Clinical Research Directory
Browse clinical research sites, groups, and studies.
Alpha-Lipoic Acid Added to Dapagliflozin and Insulin Resistance in Type 2 Diabetes
Sponsor: Fayoum University
Summary
The goal of this clinical trial is to test whether adding alpha-lipoic acid (ALA) to usual treatment with metformin and dapagliflozin improves insulin resistance in adults with type 2 diabetes mellitus. The main questions it aims to answer are: * Does ALA 600 mg once daily for 12 weeks lower insulin resistance, measured by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), more than a placebo? * Does ALA also improve blood sugar control, body weight and waist size, blood pressure, and blood fats, and is it safe and well tolerated? Participants will: * Keep taking their usual metformin and dapagliflozin 10 mg daily without any change. * Take one capsule every day for 12 weeks, either ALA 600 mg or a matching placebo (a capsule with no active ingredient), assigned by chance. * Visit the clinic at the start, at week 6, and at week 12 for blood tests, body measurements, and safety checks. Researchers will compare the ALA group with the placebo group to see if ALA lowers HOMA-IR more than placebo.
Official title: Effect of Alpha-Lipoic Acid as Add-on Therapy to Dapagliflozin on Insulin Resistance and Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Key Details
Gender
All
Age Range
30 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2026-12-01
Completion Date
2027-09-01
Last Updated
2026-11-12
Healthy Volunteers
No
Interventions
Alpha-Lipoic Acid (ALA)
Oral capsules dispensed at study visits. Unused capsules are returned and counted at Week 6 and Week 12 to measure adherence.
Placebo
Capsule with no active ingredient, dispensed and counted on the same schedule as the ALA capsule.
Locations (1)
Fayoum University
Al Fayyum, Egypt